 |
|
Images of Estrogen-Receptor-Positive Breast Tumors Produced by Estradiol Labeled With Iodine I 123 at 16
Daniel E. Kenady, MD;
Edward J. Pavlik, PhD;
Katherine Nelson, PhD;
John R. van Nagell, Jr, MD;
Holly Gallion, MD;
Paul D. DePriest, MD;
U. Yun Ryo, MD;
Richard J. Baranczuk, PhD
Arch Surg. 1993;128(12):1373-1381.
Abstract
Objective
To examine the suitability of estradiol labeled with iodine I 123 at 16 for imaging estrogenreceptor—positive breast carcinoma using imaging instrumentation that is widely available.
Design
Single-photon emission computed tomographic imaging survey of 29 women with suspected primary or expected recurrent breast carcinoma.
Setting
University-based referral center.
Participants
Twenty-nine women undergoing diagnosis for primary or recurrent breast carcinoma. Selection was voluntary.
Main Outcome Measure
Qualitative imaging study designed to provide tomographic data of radioligand retention and descriptive data of imaging results.
Results
Single-photon emission computed tomographic imaging using 123I-estradiol at 16 was performed for patients with breast carcinoma. Independent readers, without knowledge of receptor status or proven disease, interpreted the films. Scintigraphic detection was most noteworthy in patients with chest wall tumors and inflammatory breast cancer. Agreement between readers was 98% for true-negative readings and 94% for true-positive readings, but only 60% for false-positive and false-negative film readings.
Conclusions
Our results indicated that areas shown on imaging were also found to have estrogen-receptor activity and that radioligand accumulation can occur with low frequency in some surgically explored tissue. Radioligand imaging with 16-123I-estradiol can locate estrogen-receptor—positive breast tumors, including some that may be difficult to detect using conventional diagnostic imaging.
(Arch Surg. 1993;128:1373-1381)
Author Affiliations
From the Departments of Surgery (Dr Kenady), Obstetrics and Gynecology (Drs Pavlik, Nelson, van Nagell, Gallion, and DePriest), and Nuclear Medicine (Dr Ryo), University of Kentucky College of Medicine, Lexington; Veterans Affairs Medical Center, Lexington (Dr Kenady); and BioMedical Research Laboratories, Overland Park, Kan (Dr Baranczuk).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
Van Den Bossche and Van de Wiele
JCO 2004;22:3593-3607.
ABSTRACT
| FULL TEXT
|
